Latest News on KYMR

Financial News Based On Company


Advertisement
Advertisement

310,487 Kymera Therapeutics, Inc. $KYMR Shares Bought by Fisher Asset Management LLC

https://www.marketbeat.com/instant-alerts/filing-310487-kymera-therapeutics-inc-kymr-shares-bought-by-fisher-asset-management-llc-2026-11-15/
Fisher Asset Management LLC significantly increased its stake in Kymera Therapeutics, Inc. by 2,438.6% in the third quarter, purchasing 310,487 additional shares. Despite this strong institutional interest and a "Moderate Buy" consensus from analysts, Kymera reported a wider-than-expected quarterly loss and lower revenue. Furthermore, the company's CEO sold 30,000 shares in October, raising questions about insider sentiment.

How (KYMR) Movements Inform Risk Allocation Models

https://news.stocktradersdaily.com/news_release/12/How_KYMR_Movements_Inform_Risk_Allocation_Models_111226073201_1794486721.html
This article provides an analysis of Kymera Therapeutics Inc. (NASDAQ: KYMR) movements to inform risk allocation models, highlighting strong sentiment across all horizons. It presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles with specific entry, target, and stop levels. The analysis emphasizes an exceptional risk-reward short setup and provides multi-timeframe signal analysis for near-term, mid-term, and long-term horizons.

9,870 Kymera Therapeutics, Inc. $KYMR Shares Purchased by Kornitzer Capital Management Inc. KS

https://www.marketbeat.com/instant-alerts/filing-9870-kymera-therapeutics-inc-kymr-shares-purchased-by-kornitzer-capital-management-inc-ks-2026-11-09/
Kornitzer Capital Management Inc. KS increased its stake in Kymera Therapeutics, Inc. by 47.9% in the third quarter, acquiring an additional 9,870 shares to bring its total holdings to 30,490 shares valued at approximately $3.4 million. Other investment firms also expanded or initiated positions in Kymera, while the company reported a quarterly loss of $1.32 per share and revenue of $1.35 million, both falling short of analyst expectations. Despite this, analysts maintain a "Moderate Buy" consensus rating with an average price target of $139.16.

Kymera Therapeutics (KYMR) Advances KT 579 And KT 621, Is It Still 6% Undervalued?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-advances-kt-579-and-kt-621-is-it-st
Kymera Therapeutics (KYMR) reported a significant net loss in Q3 and over nine months, yet its share price has seen substantial gains year-to-date and over three years, fueled by interest in its KT-579 and KT-621 programs. The company is considered 6% undervalued with a narrative fair value of $139.83, contingent on the successful progression of these clinical candidates. However, a high price-to-book ratio of 7x, compared to an industry average of 1.7x, suggests a rich premium and highlights execution risks related to R&D spending and potential shareholder investigations.

Kymera Therapeutics, Inc. (KYMR) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/KYMR/seasonality/
The article provides a seasonal returns chart for Kymera Therapeutics, Inc. (KYMR), displaying the average monthly price return from 2020 to 2026. It includes current stock information, showing KYMR's real-time price on NasdaqGM and its performance at market close and after hours on November 6. The page is primarily a data visualization with supporting financial metrics for the company.
Advertisement

Clinical Progress May Keep Kymera Therapeutics Stock In Focus Despite Losses

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/clinical-progress-may-keep-kymera-therapeutics-stock-in-focu
Kymera Therapeutics reported a Q3 2026 net loss of US$132 million, indicating a prioritization of pipeline progress for protein degradation candidates KT-579 and KT-621 over near-term profitability. The company's investment narrative hinges on these clinical advancements, with forecast revenue of US$51.4 million and projected earnings of US$9.1 million by 2029. Despite the losses, clinical milestones for KT-621 and KT-579 are critical to the company's long-term strategy and investor confidence.

Kymera Therapeutics, Inc. (KYMR) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/KYMR/
Kymera Therapeutics, Inc. (KYMR) stock saw a decline of 5.97% during regular trading hours on November 5th, closing at $128.12. In after-hours trading, the stock fell further by 2.12% to $125.40. The article provides key financial metrics and trading data for KYMR, including its previous close, day's range, and market capitalization.

Kymera Therapeutics stock hits all-time high at 130.48 USD

https://www.investing.com/news/company-news/kymera-therapeutics-stock-hits-alltime-high-at-13048-usd-93CH-4995511
Kymera Therapeutics Inc. (KYMR) stock has reached an all-time high of $130.48, reflecting a 115.99% increase over the past year and a market capitalization of $11.05 billion. Despite being identified as overvalued by InvestingPro, the company shows strong revenue growth and a solid financial position with more cash than debt. Recent Q3 2026 results showed a narrower-than-expected loss and analysts like Oppenheimer and Brookline Capital Markets have raised their price targets, citing promising study results for KT-579.

Kymera Therapeutics to present at five September investor conferences

https://scanx.trade/stock-market-news/companies/kymera-therapeutics-present-five-september-investor-conferences/49925212
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has announced its participation in five investor conferences throughout September 2026. The clinical-stage biopharmaceutical company will engage with analysts and investors through presentations and fireside chats at events hosted by Wells Fargo, Citi, H.C. Wainwright, Morgan Stanley, and Stifel. Live webcasts and archived replays will be available on the company's website.

Kymera Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:KYMR) 2026-11-02

https://seekingalpha.com/article/4961220-kymera-therapeutics-inc-2026-q3-results-earnings-call-presentation?source=generic_rss
Kymera Therapeutics, Inc. published its 2026 Q3 earnings call slide deck. The company reported an EPS of -$1.32, missing estimates by $0.05, and revenue of $0.00, missing by $2.95M. This presentation accompanies the earnings call that occurred on November 02, 2026, at 6:28 PM ET.
Advertisement

Barclays maintains Kymera Therapeutics at Overweight, raises price target to $170 from $139

https://www.tradingview.com/news/tradingview:7d19457480466:0-barclays-maintains-kymera-therapeutics-at-overweight-raises-price-target-to-170-from-139/
Barclays has reiterated its Overweight rating on Kymera Therapeutics and increased its price target from $139 to $170, representing a 22.3% hike. This new price target suggests a potential upside of 34.2% from the stock's closing price on October 30. Other analysts have also recently issued ratings and price targets for Kymera Therapeutics, with targets ranging from $116 to $150.

Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Lowered by Wall Street Zen

https://www.marketbeat.com/instant-alerts/analyst-kymera-therapeutics-nasdaq-kymr-stock-rating-lowered-by-wall-street-zen-2026-10-31/
Wall Street Zen downgraded Kymera Therapeutics (NASDAQ:KYMR) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Moderate Buy" and an average price target of $137.92. The company's shares traded near their 12-month high, but Kymera reported weaker-than-expected third-quarter results with a $1.32 per-share loss and lower revenue, although positive Phase 1 data for KT-579 provided some clinical support. Insider transactions also showed recent share sales by the CEO and another insider.

Kymera Therapeutics (KYMR) Stock Jumps As Q3 Results Show Zero Revenue

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-stock-jumps-as-q3-results-show-zero
Kymera Therapeutics (KYMR) saw its stock jump 3.3% despite reporting zero revenue and a US$132.0 million loss for Q3 2026. The increase is attributed to optimism surrounding its drug pipeline, with clinical milestones in KT-579 and KT-621, and progress in partnerships. However, concerns remain regarding the lack of revenue, widening losses, and ongoing shareholder investigations into governance.

RBC Capital maintains Kymera Therapeutics at Sector Perform, raises price target to $116 from $112

https://www.tradingview.com/news/tradingview:63f827f4daebd:0-rbc-capital-maintains-kymera-therapeutics-at-sector-perform-raises-price-target-to-116-from-112/
RBC Capital has reaffirmed its "Sector Perform" rating for Kymera Therapeutics and increased its price target to $116 from $112. This new target suggests a 5.4% downside from the stock's closing price on October 29th. Other analysts have recently issued "Buy" or "Overweight" ratings for Kymera, with price targets ranging from $139 to $150.

Kymera Therapeutics Price Target Raised to $150.00/Share From $136.00 by Truist Securities

https://www.moomoo.com/news/post/1003042949/kymera-therapeutics-price-target-raised-to-150-00-share-from
Truist Securities has increased its price target for Kymera Therapeutics (NASDAQ: KYMR) shares to $150.00 from $136.00. This adjustment reflects a more optimistic outlook on the company's future performance. The new price target suggests potential upside for investors.
Advertisement

Oppenheimer raises Kymera Therapeutics price target on drug data

https://www.investing.com/news/analyst-ratings/oppenheimer-raises-kymera-therapeutics-price-target-on-drug-data-93CH-4984910
Oppenheimer has increased its price target for Kymera Therapeutics (NASDAQ:KYMR) to $140 from $125, maintaining an Outperform rating, following positive results from the company's KT-579 healthy volunteer study and strong third-quarter financial results. The firm anticipates further upside with forthcoming BROADEN2 dataset results for atopic dermatitis. Kymera ended the third quarter with $1.6 billion in cash, expected to fund operations until 2029, and its stock has surged over 104% in the past year.

Brookline Capital raises Kymera Therapeutics price target on reduced risk

https://www.investing.com/news/analyst-ratings/brookline-capital-raises-kymera-therapeutics-price-target-on-reduced-risk-93CH-4984815
Brookline Capital Markets increased its price target for Kymera Therapeutics (NASDAQ:KYMR) stock from $111 to $132, maintaining a Buy rating, citing reduced risks and the company's success to date. This adjustment comes as Kymera Therapeutics' stock trades near its 52-week high, with significant recent gains. Despite an estimated increase in net loss per share for 2026-2031 and decreased EPS for 2032-2035 due to revised financial forecasts, the firm lowered the estimated additional capital needed to $600 million from $800 million.

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

https://investingnews.com/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026/
Kymera Therapeutics, Inc. (NASDAQ: KYMR) will announce its third-quarter 2026 financial results on October 29, 2026, and will host a video conference call and webcast at 8:30 a.m. ET on the same day. The clinical-stage biopharmaceutical company focuses on advancing oral small molecule degrader medicines for immunological diseases. A replay of the webcast will be available following the event on the company's website.

Kymera Therapeutics Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:68e524185094b:0-kymera-therapeutics-q3-earnings-call-highlights/
Kymera Therapeutics reported its third-quarter results, highlighting progress in its clinical pipeline, particularly with positive phase I data for KT-579 in autoimmune diseases and upcoming phase IIb data for KT-621 in atopic dermatitis by year-end 2026. The company plans to initiate a phase Ib lupus study for KT-579 in early 2027 and its first phase III atopic dermatitis study for KT-621 by mid-2027. Kymera also detailed its financial position, showing a strong cash runway into 2029 despite an expected increase in operating expenses for later-stage clinical development.

KYMR: KT-579 validated IRF5 degradation in humans as KT-621 AD data approach year-end

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4383898:0-kymr-kt-579-validated-irf5-degradation-in-humans-as-kt-621-ad-data-approach-year-end/
Kymera Therapeutics (KYMR) announced positive Phase I results for KT-579, demonstrating deep IRF5 degradation, broad biomarker effects, and placebo-like safety, supporting its advancement into a lupus Phase Ib study. Additionally, the company expects Phase IIb results for KT-621 AD by year-end. With approximately $1.6 billion in cash and investments, Kymera has sufficient runway into 2029.
Advertisement

Earnings call transcript: Kymera Therapeutics misses Q3 2026 EPS, shares rise

https://ca.investing.com/news/stock-market-news/earnings-call-transcript-kymera-therapeutics-misses-q3-2026-eps-shares-rise-93CH-4914447
Kymera Therapeutics reported a narrower-than-expected Q3 2026 loss per share but its stock rose over 3% in premarket trading. The company also shared positive Phase 1 data for its IRF5 degrader, KT-579, demonstrating strong target degradation and functional modulation of immune pathways, supporting its advancement into a Phase 1b lupus trial. Despite the EPS miss, investors focused on pipeline progress and a strong balance sheet with $1.6 billion in cash, sufficient to fund operations into 2029.

Kymera to announce Phase 1 trial results for KT-579, a new oral drug for autoimmune diseases, on Oct 29, 2026

https://pluang.com/en/news-feed/kymera-therapeutics-hasil-uji-klinis-kt-579-fase-1-29-oktober-2026
Kymera Therapeutics is set to announce Phase 1 clinical trial results for KT-579, an oral drug targeting IRF5 for autoimmune diseases, on October 29, 2026. This announcement, which coincides with their third quarter 2026 financial results, is anticipated to highlight KT-579's potential as a new treatment for conditions such as lupus and rheumatoid arthritis. Investor interest is reflected in the company's stock, which saw a notable increase in trading value.

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

https://www.manilatimes.net/2026/10/29/tmt-newswire/globenewswire/kymera-therapeutics-to-announce-kt-579-phase-1-healthy-volunteer-trial-results-on-october-29-2026/2456607/amp
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is set to announce results from its Phase 1 clinical trial for KT-579 in healthy volunteers on October 29, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET to discuss these results, alongside its third-quarter 2026 financial results. KT-579 is an investigational, first-in-class oral degrader of IRF5, targeting various autoimmune diseases.

Learn Why The Bull Case For Kymera Therapeutics Stock Could Change Following Earnings Beat

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/learn-why-the-bull-case-for-kymera-therapeutics-stock-could/amp
Kymera Therapeutics is anticipated to report an earnings beat, with a projected loss of $1.26 per share and revenue of $6.05 million. The company's immunology pipeline, particularly the progress of oral STAT6 degrader KT-621 with positive Phase 1b data and rapid Phase 2b enrollment, is crucial for its investment narrative. Strong BROADEN2 data by late 2026 could support Phase 3 trials and validate revenue growth forecasts, potentially reshaping the bull case for the stock.

BlackRock reports sole voting power over 5.33M Kymera Therapeutics (KYMR) shares.

https://www.stocktitan.net/sec-filings/KYMR/schedule-13g-a-kymera-therapeutics-inc-amended-passive-investment-dis-9975297558b8.html
BlackRock, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Kymera Therapeutics, Inc. (KYMR), reporting beneficial ownership of 5,450,286 common shares, representing 6.6% of the class as of September 30, 2026. The filing indicates BlackRock holds sole voting power over 5,331,553 shares and sole dispositive power over 5,450,286 shares, with no shared voting or dispositive power. This stake is held in the ordinary course of business, without the purpose of influencing company control.
Advertisement

Morgan Stanley Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $146

https://www.moomoo.com/news/post/1002414079/morgan-stanley-initiates-kymera-therapeutics-kymrus-with-buy-rating-announces
Morgan Stanley has initiated coverage on Kymera Therapeutics (KYMR.US) with a Buy rating. The firm has set a price target of $146 for the company's stock. This initiation suggests a positive outlook from Morgan Stanley regarding Kymera Therapeutics' future performance.

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

https://www.marketbeat.com/instant-alerts/analyst-kymera-therapeutics-nasdaq-kymr-stock-price-target-raised-at-morgan-stanley-2026-10-27/
Morgan Stanley has increased its price target for Kymera Therapeutics (NASDAQ:KYMR) to $146 from $135, reiterating an "overweight" rating and suggesting a 27.13% upside. This follows Kymera's recent strong quarterly performance, which saw adjusted loss per share beat consensus and revenue increase by 465.2% year-over-year. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $135.12.

Kymera Therapeutics (KYMR) Could Be 17% Undervalued Following Its Earnings Preview

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-could-be-17-undervalued-following-i
Kymera Therapeutics (KYMR) is expected to post a loss of $1.26 per share with sharply higher revenue for the September 2026 quarter, while its stock has seen significant year-to-date and annual returns. Despite these gains, analysts believe the stock is 17% undervalued, with a fair value of $137.73 compared to its current price of $114.84, driven by the potential of its immunology pipeline and collaboration with Sanofi. Investors are weighing the pipeline's prospects against high R&D spending and clinical progress risks.

Earnings Preview: KYMR to Report Financial Results Pre-market on October 29

https://www.moomoo.com/news/post/1002243754/earnings-preview-kymr-to-report-financial-results-pre-market-on
KYMR is scheduled to report its financial results pre-market on October 29. Investors will be watching for key financial metrics and any guidance provided for future performance. This earnings report will offer insights into the company's recent operational and financial health.

Kymera Therapeutics (KYMR) Expected to Post Quarterly Earnings on Thursday

https://www.marketbeat.com/instant-alerts/upcoming-kymera-therapeutics-kymr-expected-to-post-quarterly-earnings-on-thursday-2026-10-24/
Kymera Therapeutics (NASDAQ:KYMR) is scheduled to release its Q3 2026 earnings before market open on Thursday, October 29th. Analysts anticipate a loss of $1.27 per share and revenues of $3.10 million. The company previously surpassed expectations in Q2 2026 with a smaller loss and significantly higher revenue, leading Wall Street to maintain a "Moderate Buy" consensus rating.
Advertisement

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

https://www.manilatimes.net/2026/10/23/tmt-newswire/globenewswire/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026/2452274/amp
Kymera Therapeutics, Inc. announced that it will report its third-quarter 2026 financial results on October 29, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET on the same day for investors and interested parties. Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases.

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

https://www.streetinsider.com/Globe+Newswire/Kymera+Therapeutics+to+Report+Third+Quarter+2026+Financial+Results+on+October+29%2C+2026/27222457.html
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced it will report its third-quarter 2026 financial results on October 29, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET on that day to discuss the results. Interested parties can register via a provided link or visit the Investors section of Kymera's website.

Kymera Heads Into Quarter With Revenue Pause As Year-End Eczema Readout Looms

https://finviz.com/news/407108/kymera-heads-into-quarter-with-revenue-pause-as-year-end-eczema-readout-looms
Kymera Therapeutics is approaching its Q3 report with anticipated weaker financial results compared to the previous quarter, largely due to the recognition of deferred collaboration revenue. The primary focus for investors, however, is the upcoming year-end 2026 top-line readout from its Broaden2 Phase 2b atopic dermatitis study of KT621, an oral STAT6 degrader. The company's operational execution, cash runway into 2029, and progress on other pipeline assets like KT579 and KT485 are also key factors influencing investor sentiment.

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

https://finance.yahoo.com/healthcare/articles/kymera-therapeutics-report-third-quarter-200100296.html
Kymera Therapeutics, Inc. announced it will report its third quarter 2026 financial results on October 29, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET on that day to discuss the results. Interested parties can register via a provided link or visit the Investors section of the company's website.

KYMR Q3'26 Earnings: revenue estimate is 3.10M USD

https://www.tradingview.com/news/tradingview:73a4713e0bbcb:0-kymr-q3-26-earnings-revenue-estimate-is-3-10m-usd/
Kymera Therapeutics, Inc. (KYMR) is scheduled to release its Q3'26 results on October 29. Analysts estimate revenue for the quarter to be $3.10 million, with an anticipated EPS of ($1.27). The article provides a table detailing past revenue and EPS reports and estimates, along with surprise percentages.
Advertisement

Form 144 Kymera Therapeutics For: 19 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-kymera-therapeutics-for-19-october-93CH-4887261
This article from Investing.com announces a Form 144 filing for Kymera Therapeutics related to October 19. It reiterates this information and provides the stock symbol KYMR, noting a 4.99% gain.

Form 144 Kymera Therapeutics For: 19 October By Investing.com

https://za.investing.com/news/stock-market-news/form-144-kymera-therapeutics-for-19-october-93CH-4510677
This article from Investing.com announces the filing of Form 144 for Kymera Therapeutics (KYMR) on October 19, 2026. The stock symbol KYMR showed a gain of 3.32% in this report. The content primarily serves as a notification of this financial filing, with minimal descriptive text.

Form 144 Kymera Therapeutics For: 19 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-kymera-therapeutics-for-19-october-93CH-2742499
This article from Investing.com announces a Form 144 filing for Kymera Therapeutics (KYMR) on October 19, 2026. Form 144 filings typically indicate an insider's intent to sell restricted stock. The article itself is brief, primarily serving as an alert for this financial event.

Form 144 Kymera Therapeutics For: 19 October By Investing.com

https://in.investing.com/news/stock-market-news/form-144-kymera-therapeutics-for-19-october-93CH-5639342
This article announces the filing of Form 144 by Kymera Therapeutics on October 19, focusing on stock market-related news. It is a very brief notification without additional details, embedded within a larger financial news platform. The article highlights the company's stock symbol KYMR and its price performance for the day.

Wells Fargo Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $151

https://www.moomoo.com/news/post/1001309478/wells-fargo-maintains-kymera-therapeutics-kymrus-with-buy-rating-maintains
Wells Fargo has reiterated its Buy rating for Kymera Therapeutics (KYMR.US) and maintained a target price of $151. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
Advertisement

Raymond James sets USD 140 target for Kymera Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/raymond-james-sets-usd-140-target-for-kymera-therapeutics-stock/70334532
Raymond James initiated coverage on Kymera Therapeutics (KYMR) with an Outperform rating and a USD 140.00 price target. This follows Citi's recent increase of its target to USD 150.00, driven by an anticipated readout for KT-621 in atopic dermatitis. Kymera Therapeutics reported strong Q2 2026 revenues of USD 65.00 million, significantly exceeding expectations, and better-than-expected adjusted loss per share.

Raymond James set a USD 140.00 target for Kymera Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/raymond-james-set-a-usd-140-00-target-for-kymera-therapeutics-stock/70318613
Raymond James initiated coverage of Kymera Therapeutics (KYMR) with an Outperform rating and a $140.00 price target on October 8, 2026. This follows Citi raising its target to $150.00 from $135.00 on October 5, 2026, citing the expected KT-621 readout in atopic dermatitis. Kymera Therapeutics reported Q2 2026 revenue of $65.00 million, a 465.20% increase year-over-year, and a narrower-than-expected adjusted loss.

Understanding Momentum Shifts in (KYMR)

https://news.stocktradersdaily.com/news_release/38/Understanding_Momentum_Shifts_in_KYMR_101226101602_1791857762.html
Kymera Therapeutics Inc. (KYMR) is experiencing a mid-channel oscillation pattern with positive near-term sentiment that may erode a mid-term weak bias within a long-term strength context. AI models have generated three distinct trading strategies for various risk profiles, including position, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. Multi-timeframe analysis shows strong signals in the near and long term, but weak signals in the mid-term.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

https://www.prnewswire.com/news-releases/shareholder-alert-purcell--lefkowitz-llp-announces-shareholder-investigation-of-kymera-therapeutics-inc-nasdaq-kymr-302905278.html
Purcell & Lefkowitz LLP has initiated a shareholder investigation into Kymera Therapeutics, Inc. (NASDAQ: KYMR) to determine if the company's directors breached their fiduciary duties through recent corporate actions. Shareholders of Kymera Therapeutics are encouraged to contact the firm for more information regarding their rights and options. Purcell & Lefkowitz LLP specializes in representing shareholders affected by securities fraud and corporate misconduct.

Kymera Therapeutics Initiated at Outperform by Raymond James

https://www.moomoo.com/news/post/1000838265/kymera-therapeutics-initiated-at-outperform-by-raymond-james
Raymond James has initiated coverage on Kymera Therapeutics (NASDAQ: KYMR) with an "Outperform" rating. This new rating suggests that the firm believes Kymera's stock will perform better than the average market or sector. The initiation of coverage by a prominent financial institution like Raymond James can often lead to increased investor interest and stock movement for the company.
Advertisement

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Has Average Target Price of $134.68

https://www.marketbeat.com/instant-alerts/consensus-kymera-therapeutics-inc-nasdaq-kymr-stock-has-average-target-price-of-13468-2026-10-10/
Kymera Therapeutics (NASDAQ:KYMR) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $134.68. The company recently surpassed earnings expectations, reporting a loss of $0.62 per share against an anticipated $0.71 loss, and significantly increased revenue by 465.2% year-over-year to $65 million. Despite analyst confidence and strong revenue growth, the company remains unprofitable with a negative net margin of 285.33%, and insiders have recently sold shares.

Kymera Therapeutics Price Target Announced at $140.00/Share by Raymond James

https://www.moomoo.com/news/post/1000838264/kymera-therapeutics-price-target-announced-at-140-00-share-by
Raymond James has set a price target of $140.00 per share for Kymera Therapeutics, indicating a significant potential upside for the stock. This new target suggests confidence in the company's future performance. Investors and market watchers will likely monitor Kymera Therapeutics closely following this analyst rating.

Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon

https://seekingalpha.com/article/4952957-kymera-stock-overhyped-or-developing-next-dupixent
Kymera Therapeutics is nearing a crucial data readout for its oral STAT6 degrader, KT-621, for atopic dermatitis, which could position it as a best-in-class alternative to Dupixent. A positive outcome from the BROADEN2 Phase 2b trial could significantly increase Kymera's valuation, while a negative result could lead to a substantial stock decline. Despite the binary risk, the author maintains a Buy rating due to the transformative potential and the company's differentiated protein degrader platform.

Raymond James initiates Kymera Therapeutics stock coverage with outperform rating

https://www.investing.com/news/analyst-ratings/raymond-james-initiates-kymera-therapeutics-stock-coverage-with-outperform-rating-93CH-4939873
Raymond James has initiated coverage on Kymera Therapeutics (NASDAQ:KYMR) with an Outperform rating and a $140.00 price target, citing the company's progress in developing small molecule targeted protein degraders for autoimmune and inflammatory conditions. The firm highlights Kymera's lead pipeline candidate, KT-621, an oral STAT6 degrader, and anticipates key Phase 2b trial results by year-end 2026. Despite the stock's significant return over the past year, InvestingPro analysis suggests it may be overvalued, although Wall Street analysts generally maintain a bullish outlook.

Raymond James initiates Kymera Therapeutics stock coverage with outperform rating

https://in.investing.com/news/stock-market-news/raymond-james-initiates-kymera-therapeutics-stock-coverage-with-outperform-rating-93CH-5625019
Raymond James has initiated coverage on Kymera Therapeutics (NASDAQ: KYMR) with an Outperform rating and a $140 price target, suggesting a potential upside of approximately 28% from its current trading price of $109.34. The firm highlights Kymera's pipeline of small molecule targeted protein degraders for autoimmune and inflammatory conditions, particularly KT-621, which is currently in a Phase 2b trial for atopic dermatitis with results expected by year-end 2026. This positive outlook aligns with other analysts who maintain a bullish stance on the company, citing its strong drug pipeline and clinical progress.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement